louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02074670: fMRI In Spinal Cord Injury Patient After Rehabilitation
Official title: FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI) OF THE SENSORIMOTOR CORTEX IN SPINAL CORD INJURY PATIENT AFTER INTENSIVE REHABILITATION INCLUDING ROBOTIC DEVICES
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Cord Injury
Lead sponsor: University of Nove de Julho
Sponsor class: OTHER
Collaborators: name: Universidade do Vale do Paraíba
name: University of Barcelona
First posted: 2014-02-28
Enrollment: 7
Sex: ALL
Minimum age (years): 15
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to evaluate the potential reorganization in the sensorimotor cortex in spinal cord injury (SCI) patients after Body Weight Supported Treadmill Training (BWSTT) associated with conventional motor rehabilitation. The investigators hypothesized that training with weight bearing associated with conventional motor rehabilitation will be able to reorganize the brain.


Eligibility criteria: Inclusion Criteria:

* Patients with ASIA C or D and the ability to cooperate with instructions of the motor task required. The motor task was to perform ankle plantar flexion and toe flexion and fingers and thumbs movement of the both sides; they also had to be able to fulfill the general conditions necessary for an MRI exploration.

Exclusion Criteria:

* Patients with uncontrollable spasticity-induced body movements were excluded from the study.

Primary outcomes:
measure: Cortical Motor Area
timeFrame: 1 month
Secondary outcomes:
measure: Functional Index
timeFrame: 1 month
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Paulo Roberto Garcia Lucareli
Study officials:
References:
Clinical trial NCT05996770: Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19
Official title: Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Paxlovid
Azvudine
COVID-19
Keywords: Paxlovid
Azvudine
COVID-19
effectiveness
real-world evidence
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2023-08-18
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All inpatients who were treated with nimatevir/ritonavir tablets and azivudine tablets at the First Affiliated Hospital of Shandong First Medical University from December 1,2022 to January 31,2023.

Brief summary: In this retrospective study, we aimed to evaluate the clinical efficacy and safety of two antiviral drugs on COVID-19 and inpatients with existing complications in the First Affiliated Hospital of Shandong First Medical University. In addition, we also explored a key issue. Is the combined treatment effect of two antiviral drugs, Paxlovid and Azvudine, better than the use of a single drug?

Detailed description: We conducted a single center retrospective cohort study on hospitalized patients with severe acute respiratory syndrome coronavirus type 2 infection who received treatment with nimatevir/ritonavir tablets or azivudine tablets at the First Affiliated Hospital of Shandong First Medical University from December 1，2022 to January 31，2023. In the research of this project, it is necessary to extract, sort out and retrospectively analyze the clinical data of all patients with COVID-19 who have received Nematovir/Ritonavir tablets or Azivudine tablets in the First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital), and respectively identify the relevant epidemiological characteristics of COVID-19 patients, It is planned to use multiple linear regression or logical regression model to explore the relevant factors that affect the drug use efficiency index, safety index and total cost of patients with COVID-19, so as to provide scientific and quantitative evidence support for the drug use mode of the disease, the clinical value of the drug and the rational drug use of patients, and also provide favorable basis for the supervision and decision-making of smart pharmacy of medical institutions.

Eligibility criteria: Inclusion Criteria:

* 1. The patient's admission time is from December 1,2022 to January 31,2023. 2. The patient has used either Paxlovid or azivudine tablets during admission. 3. Age ≥ 18 years old. Exclusion Criteria：
* 1. Patients using other antiviral drugs. 2. Patients with incomplete clinical data.

Primary outcomes:
measure: mortality
timeFrame: Through study completion，up to half a year.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01034670: Advanced Gastrointestinal Endoscopic Imaging
Official title: Advanced Gastrointestinal Endoscopic Imaging
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Gastrointestinal Diseases
Gastric (Stomach) Cancer
Gastrointestinal Stromal Tumor (GIST)
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
name: National Cancer Institute (NCI)
First posted: 2009-12-17
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To develop new methods to detect malignant and premalignant conditions of the gastrointestinal tract.


Eligibility criteria: Inclusion Criteria:patients be at least 18 years of age,

Either genders

All ethnic backgrounds will be considered.

Patients who are scheduled for endoscopy by one of the investigators will be asked if they are interested in participating in the study.

The study will be open to all patients undergoing endoscopy that do not have exclusion criteria. We will ask all patients if they are participating in any other studies. If they are participating in any other study then we will ask them for more information to determine whether there could be any harm from participating in both studies and if there is then they will not be enrolled. Exclusion Criteria:Patients with unstable vital signs will not be included.

Primary outcomes:
measure: Number of Participants With Successful Imaging of the Mucosa
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Shai Friedland
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02671370: Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study
Official title: Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neck Pain
Lead sponsor: Balgrist University Hospital
Sponsor class: OTHER
Collaborators: name: Maastricht University
First posted: 2016-02-02
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Participants with neck pain of any duration

Brief summary: This study there are any associations between objective and subjective outcome measures, measuring the cervical range of motion and if the restriction matter to the patient.

Detailed description: Objective and subjective outcome measures are frequently used assessments in clinical practice.

The investigators will use different subjective and objective outcome measures to evaluate any possible associations, as well as to investigate if restrictions of movement matters to patients.

Additionally to the assessments tools the investigators will use interviews to extend the scope.

Eligibility criteria: Inclusion Criteria:

* Patients with any duration of neck pain
* Men and women older than 18 years
* Signed informed consent

Exclusion Criteria:

* Disc herniation of the cervical spine
* Spinal canal stenosis
* Acute accidents
* Surgery of the cervical spine
* Pacemaker and / or defibrillator

Primary outcomes:
measure: Cervical Range of Motion (CROM)
timeFrame: Baseline
Secondary outcomes:
measure: Neck Disability Index
timeFrame: Baseline
measure: S-ROM-Neck
timeFrame: Baseline
measure: Interviews (personal,semi-structured guided, open-ended questions) in a one-to-one Setting. Recorded with a voice-recorder.
timeFrame: Baseline
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: Balgrist University Hospital
Study officials:
affiliation: Balgrist University Hospital
name: Jaap Swanenburg, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02670070: BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone
Official title: A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Healthy
Lead sponsor: LG Life Sciences
Sponsor class: INDUSTRY
First posted: 2016-02-01
Enrollment: 37
Sex: MALE
Minimum age (years): 19
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Detailed description: This study is to evaluate the safety/tolerability and pharmacokinetics(AUC and Cmax) of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Eligibility criteria: Inclusion Criteria:

* Age between 19 to 45, healthy male subjects(at screening)
* BMI between 18.0 - 27.0
* FPG 70-125mg/dL glucose level(at screening)
* Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.

Exclusion Criteria:

* Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
* Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)
* Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)
* Subject who already participated in other trials in 2months
* Subject who had whole blood donation in 2 months, or component blood donation in 1 month or transfusion in 1 month currently.
* Heavy smokers.(\>10 cigarettes per day)

Primary outcomes:
measure: AUClast, Cmax
timeFrame: up to 72h post-dose
Secondary outcomes:
measure: AUCinf
timeFrame: up to 72h post-dose
measure: Tmax
timeFrame: up to 72h post-dose
measure: t1/2
timeFrame: up to 72h post-dose
measure: CL/F
timeFrame: up to 72h post-dose
measure: metabolic ratio
timeFrame: up to 72h post-dose
measure: AUEC
timeFrame: up to 72h post-dose
measure: Emax
timeFrame: up to 72h post-dose
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Kyung Sang Yu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04612270: Quantification of Clinically Relevant Drug Induced Changes in HbO2 Affinity
Official title: Quantification of Clinically Relevant Drug Induced Changes in HbO2 Affinity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Oxygen Deficiency
Lead sponsor: Medical University Innsbruck
Sponsor class: OTHER
First posted: 2020-11-02
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The presented study is an experimental in-vitro study without intervention in-vivo. The effects of nitric oxide and prostacyclins, 5-hydroxymethylfurfural and alpha-ketoglutarate, volatile anaesthetics on haemoglobin oxygen (HbO2) affinity will be investigated in-vitro. Venous blood samples of 20 healthy young volunteers (10 female, 10 male) will be collected twice in the period of one week. Informed consent will be given. Every blood collection will be accompanied by a venous blood gas analysis. The blood samples will be transferred to the laboratory for in-vitro recording of the complete oxygen dissociation curve (ODC). A newly developed in-vitro method will be used. On the first study day the blood samples will be exposed to three different concentrations of nitric oxide during the measurement, followed by two different vapourized prostacyclins. In addition, different concentrations of 5-hydroxymethylfurfural and alpha-ketoglutarate will be given to the blood samples for ODC recording. On the second study day the dose dependent effects of three different volatile anaesthetics will be investigated by exposing the blood samples to these drug while the measurements. Following these ODC recordings, aliquots of the blood samples will be frozen and investigated for storage related changes in HbO2 affinity.


Eligibility criteria: Inclusion Criteria:

* Informed consent
* ASA 1 (American Society of Anesthesiologists classification)

Exclusion Criteria:

* Any drug intake within 10 days prior to blood collection
* Smoking
* Haemoglobinopathy
* Acute inflammatory disease within 14 days prior to blood collection
* Pregnancy or breastfeeding
* Severe trauma or blood loss within 14 days prior to blood collection
* Participation in any other clinical study
* High altitude sojourn for several days (\> 3,000 m) within four weeks prior to blood collection

Primary outcomes:
measure: P50
timeFrame: One day
Secondary outcomes:
measure: Hill coefficient
timeFrame: One day
Other outcomes:
Locations:
city: Innsbruck
country: Austria
facility: Department of Anaesthesiology and Critical Care Medicine
state: Tyrol
Study officials:
affiliation: MUI, Department of Anaesthesiology and Critical Care Medicine
name: Mathias Ströhle, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ronzani M, Woyke S, Mair N, Gatterer H, Oberacher H, Plunser D, Haller T, Strohle M, Rugg C. The effect of desflurane, isoflurane and sevoflurane on the hemoglobin oxygen dissociation curve in human blood samples. Sci Rep. 2022 Aug 10;12(1):13633. doi: 10.1038/s41598-022-17789-6.
Clinical trial NCT06767670: The Relation Between Oral Hygiene and Microbial Load in the Oral Cavity After Restoring Primary Molars With Two Types of Ready-made Crowns
Official title: Evaluation of Oral Hygiene Status in Correlation With Microbial Load in the Oral Cavity Following Restorations of Primary Molars Using Stainless Steel and Bioflex Crowns (Clinical Randomized Trial)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Carious Lesion
Ready-made Crowns
Keywords: primary crowns,
oral health
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2025-01-10
Enrollment: 40
Sex: ALL
Minimum age (years): 4
Maximum age (years): 8
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 10 patients 4-8 years old will be selected according to the established inclusion and exclusion criteria. The study will be conducted on patients attending the outpatient clinic of the pediatric dentistry department, Faculty of Dental Medicine Al-Azhar.

Brief summary: Following the restoration of primary molars with stainless steel and bioflex crowns, an evaluation of the current state of oral hygiene in relation to the amount of microorganisms and gingival health in the oral cavity will be carried out.


Eligibility criteria: Inclusion Criteria:

* Participants aged between 4 and 8 years.
* Pulp therapy treated primary molars on the contralateral side, requiring a full coverage restoration (split-mouth technique).
* No history of any antibiotic consumption 2 weeks before the procedure.
* No history of fluoride application 2 weeks before the procedure.

Exclusion Criteria:

* Special children with physical disabilities or emotional disturbances.
* Children are diagnosed with systemic diseases.
* Grossly destructed teeth with non-restorable crown structure.
* Primary teeth with shedding or pathological tooth mobility.

Primary outcomes:
measure: The adhesion of S. mutans to prefabricated Bioflx and Stainless-steel crowns under clinical conditions.
timeFrame: one months
Secondary outcomes:
measure: Gingival health
timeFrame: one months
measure: Plaque Index (PI)
timeFrame: one month
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University
state: Nasr City
city: Cairo
country: Egypt
facility: Faculty of Dental Medicine at Al-Azhar University.
state: Nasr City
Study officials:
affiliation: Al-Azhar University
name: Alaa Mohammed Eldehna, Assistant Proffessor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00601770: Virological Response Study of the HCV Vaccine IC41
Official title: Open-label, Multicenter Trial With IC41, a Therapeutic HCV Vaccine in Patients With Chronic HCV
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C
Lead sponsor: Valneva Austria GmbH
Sponsor class: INDUSTRY
First posted: 2008-01-28
Enrollment: 71
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41.

Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.


Eligibility criteria: Inclusion Criteria:

* Written informed consent obtained prior to study entry
* Patients with chronic hepatitis C; genotype 1
* Treatment naive patients
* Male and Female, 18 to 55 years
* Presence of HLA-A2 marker
* Mentally healthy
* No clinically relevant pathological findings in any of the investigations at screening
* Treatment naive patients with chronic Hepatitis C of genotype 1

Exclusion Criteria:

* Positive results in HIV, HBsAg and HAV-Ag (IgM)
* Other causes of chronic hepatitis
* History of autoimmune diseases
* Previous vaccination with any prophylactic or therapeutic Hepatitis C vaccine (in a clinical study)
* Active or passive vaccination 4 weeks before and during the entire study period
* Decompensated liver disease
* History of severe hypersensitivity reactions and anaphylaxis
* Known allergic reactions to one of the components of the vaccine and Imiquimod cream
* Clinically significant diseases which, in the opinion of the Investigator, might lead to frequent hospitalization/medical attendance
* Malignancies
* Immunosuppressive therapy
* Pregnancy, lactation or breast-feeding
* Unwillingness to practice appropriate contraception
* Participation in another study with an investigational drug within 1 month prior to enrolment and the entire study period
* Patients, who in the opinion of the Investigator, might not be able to comply with the study protocol (e.g.: Drug addiction, alcoholism)

Primary outcomes:
measure: HCV-RNA 2 weeks after end of treatment
timeFrame: 2 weeks
Secondary outcomes:
measure: Immunological assays and Safety
timeFrame: until study end
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Prof. Dr. Ulrich Spengler
city: Hannover
country: Germany
facility: Prof. Dr. Michael Manns
city: Warzawa
country: Poland
facility: Dr. Granzyna Cholewinska-Szymanska
city: Wroclaw
country: Poland
facility: Prof. Dr. Andrzej Gladszy
city: Bucharest
country: Romania
facility: Prof. Dr. Mircea Diculescu
city: Bucharest
country: Romania
facility: Dr. Adriana Motoc
city: Bucharest
country: Romania
facility: Dr. Adriana Hristea
city: Iasi
country: Romania
facility: Prof. Dr. Carol Stanciu
Study officials:
affiliation: Valneva Austria GmbH
name: Sonja Ernsthofer, Mag
role: STUDY_DIRECTOR
References:
Clinical trial NCT01487070: A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Official title: A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: PDR
Lead sponsor: Retina Institute of Hawaii
Sponsor class: OTHER
First posted: 2011-12-07
Enrollment: 5
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary objective of this trial will be to evaluate the safety and efficacy of intravitreal injections of Macugen (pegaptanib sodium) when given at least 7-14 days prior to vitrectomy in subjects with tractional retinal detachment (with or withoutmacular involvement) secondary to proliferative diabetic retinopathy.

Secondary objective is to evaluate regression of neovascularization and progression of macular traction utilizing OCT and fundus photographs.


Eligibility criteria: Inclusion Criteria:

* Subjects of either gender aged 75 years or below diagnosed with tractional retinal detachment secondary to proliferative diabetic retinopathy.

Exclusion Criteria:

* Subjects with vitreous hemorrhage obscuring the posterior pole will be excluded.

Primary outcomes:
measure: Evidence of advancement of tractional detachment post injection of Macugen before surgical intervention.
timeFrame: 7-14 days prior to surgical intervention
Secondary outcomes:
measure: Evaluate regression of neovascularization and progression of macular traction utilizing OCT and Fundus photographs
timeFrame: 7-14 days prior to surgical intervention
Other outcomes:
Locations:
city: Honolulu
country: United States
facility: Retina Institute of Hawaii
state: Hawaii
Study officials:
References: